JPRN-UMIN000006899已完成2 期
Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapy - Phase II study of biweekly cetuximab vs. panitumumab for KRAS wild-type colorectal cancer.
Tsukuba Center Clinical Trial Group(TCTG)0 个研究点目标入组 90 人开始时间: 2011年12月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)having other active malignancies 2) severe complications (uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, heart failure ,renal failure, hepatic failure, etc.) 3) having active infections 4) history of severe drug hypersensitivity 5) uncontrollable serious mental problem 7) pregnant or female intend to be pregnant, and male intend to make pregnant. 8) Others
研究者
相似试验
已完成
2 期
Phase II study of biweekly cetuximab therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011361Department of Surgical Oncology Osaka City University10
进行中（未招募）
不适用
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapyPatients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-002811-98-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE100
进行中（未招募）
1 期
Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus CETuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or METastatic squamous cell carcinoma of the head and neck - CETMETPatients with metastatic or recurrent squamous cell carcinoma of the head and neck, not suitable for local treatmentMedDRA version: 19.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022924-57-DKRadiumhemmet, Karolinska University Hospital, Stockholm, Sweden120
进行中（未招募）
1 期
Randomised phase II study with cetuximab (Erbitux®) in combination with chemotherapy (5-FU and cisplatin or carboplatin) versus cetuximab (Erbitux®) in combination with chemotherapy (paclitaxel and carboplatin) for treatment of patients with relapsed or metastatic head and neck cancerPatients with relapsed or metastatic squamous cell carcinoma of the head and neckPreviously not treated for relapsed or metastatic SCCHN.EUCTR2010-022924-57-SERadiumhemmet Karolinska University Hospital120
已完成
2 期
Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancerrecurrent or metastatic colorectal cancerJPRN-UMIN000006452Kobe University Hospital20